Experimental monoclonal antibodies show promise against Epstein-Barr virus

A panel of investigational monoclonal antibodies (mAbs) targeting different sites of the Epstein-Barr virus (EBV) blocked infection when tested in human cells in a laboratory setting. Moreover, one of the experimental mAbs provided nearly complete protection against EBV infection and lymphoma when tested in mice.

Leave a Comment

Your email address will not be published.

Generated by Feedzy